Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Pembrolizumab in recurrent or metastatic medullary thyroid cancer.
Journal: The oncologist
Published: August 14, 2025
A phase 2 study of GI-6207 in patients with recurrent medullary thyroid cancer.
Journal: The oncologist
Published: August 14, 2025
Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study.
Journal: ESMO open
Published: September 08, 2022
A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin.
Journal: Investigational new drugs
Published: January 07, 2022
A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer.
Journal: Frontiers in endocrinology
Published: April 23, 2020
Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma.
Journal: Thyroid : official journal of the American Thyroid Association
Published: June 01, 2013
Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.
Journal: The Journal of clinical endocrinology and metabolism
Published: April 17, 2013
Cancer: thyroid cancer bone metastases and high morbidity rates.
Journal: Nature reviews. Endocrinology
Published: July 04, 2012
Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer.
Journal: Surgery
Published: March 01, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026